Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2019 to Oct 2024
Affymetrix, Inc. (Nasdaq:AFFX) today announced that Greg
Schiffman, Executive Vice President and CFO, will provide a company
overview at the Nasdaq 17th Investor Program Healthcare Forum in
London, UK. A live transmission of the presentation will take place at
9:15 a.m. local time (2:15 p.m. ET) on Wednesday June 21, 2006. An
archived webcast will be available for 30 days.
To access the live webcast or archived presentation, find the
"Investors" link in the "Resources for" drop-down menu on
www.affymetrix.com.
About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become the
industry standard in molecular biology research. Affymetrix technology
is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have been
installed around the world and nearly 4,000 peer-reviewed papers have
been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the most information
capacity available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between genetics
and health. Affymetrix is headquartered in Santa Clara, Calif., with
manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The
company maintains important sales and marketing operations in Europe
and Asia and has about 1,100 employees worldwide. For more information
about Affymetrix, please visit the company's website at
www.affymetrix.com.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix, Inc.